Primary and secondary outcome measures for this study
| Drug | Estimated change from placebo | |
|---|---|---|
| Baseline adjusted estimate (95% CI), p value | Fully adjusted* estimate (95% CI), p value | |
| Bacterial load by quantitative culture (log10 cfu/mL) | ||
| Moxifloxacin | −0.32 (−0.81 to 0.17) p=0.20 | −0.42 (−0.91 to 0.08) p=0.10 |
| Doxycycline | −0.05 (−0.50 to 0.40), p=0.82 | −0.11 (−0.55 to 0.33), p=0.62 |
| Azithromycin | −0.17 (−0.62 to 0.29), p=0.47 | −0.08 (−0.54 to 0.38), p=0.73 |
| Bacterial load by 16S qPCR (log10 copies/g of sputum) | ||
| Moxifloxacin | 0.14 (−0.42 to 0.69), p=0.63 | 0.30 (−0.30 to 0.89), p=0.33 |
| Doxycycline | 0.06 (−0.49 to 0.60), p=0.84 | 0.16 (−0.40 to 0.72), p=0.58 |
| Azithromycin | 0.28 (−0.27 to 0.83), p=0.33 | 0.32 (−0.24 to 0.88), p=0.27 |
| FEV1, mL | ||
| Moxifloxacin | 39 (−84 to 161), p=0.54 | 58 (−74 to 190), p=0.39 |
| Doxycycline | 31 (−89 to 151), p=0.61 | 39 (−85 to 162), p=0.54 |
| Azithromycin | 1 (−123 to 124), p=0.99 | −1 (−126 to 125), p=0.99 |
| SGRQ total score | ||
| Moxifloxacin | −2.25 (−8.60 to 4.09), p=0.49 | −1.88 (−8.59 to 4.84), p=0.59 |
| Doxycycline | 0.88 (−5.30 to 7.06), p=0.78 | 1.02 (−5.28 to 7.31), p=0.75 |
| Azithromycin | −2.35 (−8.44 to 3.73), p=0.45 | −2.29 (−8.43 to 3.86), p=0.47 |
| Adherence to treatment. OR (95% CI) | ||
| Moxifloxacin | 0.89 (0.05 to 15.09), p=0.94 | 0.74 (0.04 to 15.61), p=0.85 |
| Doxycycline | 0.64 (0.05 to 9.02), p=0.74 | 0.60 (0.04 to 9.68), p=0.72 |
| Azithromycin | 1.34 (0.07 to 26.06), p=0.84 | 2.42 (0.09 to 63.28), p=0.60 |
| Exacerbation frequency. Relative risk (95% CI) | ||
| Moxifloxacin | 1.36 (0.62 to 2.97), p=0.44 | 1.38 (0.62 to 3.10), p=0.43 |
| Doxycycline | 2.05 (0.98 to 4.29), p=0.06 | 2.07 (0.99 to 4.35), p=0.05 |
| Azithromycin | 0.83 (0.35 to 1.93), p=0.66 | 0.72 (0.30 to 1.71), p=0.45 |
| Antibiotic resistance testing | ||
| Factor change in MIC | ||
| Moxifloxacin | 4.82 (1.44 to 16.19), p=0.01 | |
| Doxycycline | 3.74 (1.46 to 9.58), p=0.01 | |
| Azithromycin | 6.23 (1.66 to 23.35), p=0.01 | |
| OR for resistant isolates | ||
| Moxifloxacin | 2.03 (0.36 to 11.54, p=0.42 | |
| Doxycycline | 5.77 (1.40 to 23.74, p=0·02) | |
| Azithromycin | 2.42 (0.61 to 9·62, p=0.21) | |
| Sputum inflammatory markers | ||
| IL-1β (log10 pg/mL) | ||
| Moxifloxacin | −0.25 (−0.63 to 0.14), p=0.21 | −0.15 (−0.56 to 0.26), p=0.47 |
| Doxycycline | −0.10 (−0048 to 0.28), p=0.61 | −0.03 (−0.43 to 0.37), p=0.88 |
| Azithromycin | 0.04 (−0.35 to 0.43), p=0.86 | 0.09 (−0.31 to 0.49), p=0.66 |
| IL-6 (log10 pg/mL) | ||
| Moxifloxacin | −0.16 (−0.50 to 0.18), p=0.37 | −0.22 (−0.59 to 0.16), p=0.27 |
| Doxycycline | −0.21 (−0.56 to 0.13), p=0.22 | −0.23 (−0.58 to 0.13), p=0.25 |
| Azithromycin | −0.19 (−0.43 to 0.27), p=0.65 | −0.06 (−0.42 to 0.30), p=0.77 |
| IL-8 (log10 pg/mL) | ||
| Moxifloxacin | −0.26 (−0.72 to 0.19), p=0.26 | −0.29 (−0.78 to 0.19), p=0.24 |
| Doxycycline | −0.11 (−0.55 to 0.34), p=0.64 | −0.08 (−0.54 to 0.38), p=0.74 |
| Azithromycin | 0.00 (−0.46 to 0.46), p=1.00 | 0.02 (−0.45 to 0.49), p=0.94 |
*The results in the right hand column were adjusted for age, sex, smoking status, FEV1% predicted and prior exacerbation history. p Values were calculated using the Wald test.
IL, interleukin; MIC, mean inhibitory concentration; qPCR, quantitative PCR; SGRQ, St George's Respiratory Questionnaire.